Clinical evidence from MINDACT

Evidence / Adjuvant / MINDACT

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial

PUBLICATION: European Journal of Cancer AUTHORS: Valesca P. Retel, Danalyn Byng, Sabine C. Linn, Katarzyna Jozwiak, Hendrik Koffijberg, Emiel J. Rutgers, Fatima Cardoso, Martine J. Piccart, Coralie Poncet, Laura J. van ’t Veer, Wim H. van Harten. Abstract: The clinical utility of the 70-gene signature (MammaPrint®) to guide chemotherapy Read More

Controlling Technical Variation Amongst 6693 Patient Microarrays of the Randomized MINDACT Trial

PUBLICATION: Communications Biology AUTHORS: Laurent Jacob, Anke Witteveen, Inès Beumer, Leonie Delahaye, Diederik Wehkamp, Jeroen van den Akker, Mireille Snel, Bob Chan, Arno Floore, Niels Bakx, Guido Brink, Coralie Poncet, Jan Bogaerts, Mauro Delorenzi, Martine Piccart, Emiel Rutgers, Fatima Cardoso, Terence Speed, Laura van ’t Veer, and Annuska Glas Abstract: Read More

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline

PUBLICATION: Journal of Clinical Oncology 37, no. 22 (August 01, 2019) 1965-1977. DOI: 10.1200/JCO.19.00948. AUTHORS: N. Lynn Henry, MD, PhD; Mark R. Somerfield, PhD; Vandana G. Abramson, MD; Nofisat Ismaila, MD; Kimberly H. Allison, MD; Carey K. Anders, MD; Diana T. Chingos, MS, MFA; Andrea Eisen, MD; Bruno L. Ferrari, Read More